Oncternal Therapeutics gets FDA orphan drug designations for cirmtuzumab ROR1 antibody to treat MCL and CLL

This article was originally published here

Cirmtuzumab is an investigational anti-ROR1 monoclonal antibody being evaluated in clinical trials in patients with MCL, CLL and HER2-negative breast cancer. Under the Orphan Drug Act, the FDA

The post Oncternal Therapeutics gets FDA orphan drug designations for cirmtuzumab ROR1 antibody to treat MCL and CLL appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply